Document is current
Any future updates will be listed below
-
Authors
Stark, Klaus J. https://orcid.org/0000-0002-7832-1942
Zimmermann, Martina E.
Helbig, Horst
Heid, Iris M.
Brandl, Caroline
-
Funding
Funding for this research was provided by:
Universitätsklinikum Regensburg
- License Information
-
More Information
Article History
Received: 22 January 2025
Revised: 20 June 2025
Accepted: 11 July 2025
First Online: 5 August 2025
Declarations
:
: This work was presented at the 122nd congress of the German Society of Ophthalmology (DOG) 2024 in Berlin, for which the authors K.J.S. and C.B. were reimbursed accommodation costs by Bayer. Author I.M.H. has received support from Roche Diagnostics for a biomarker project in the AugUR study, but unrelated to the work presented here. H. H.: Advisory board and lecture fees from: Abbvie, Alcon, Apellis, Astellas, Bayer, Novartis, Roche, Theapharm. The companies had no influence on the analysis of the data and the type of presentation.
: Not applicable.
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Review Board of the University of Regensburg (IRB number: 12-101-0258).
: Written informed consent was obtained from all individual participants included in the study.
